Is Tango Therapeutics (TNGX) Undervalued As Phase 3 Plans Follow Strong Trial Data?
Tango Therapeutics (TNGX) is back in focus after releasing updated Phase 1/2 data for vopimetostat plus RAS inhibitors in MTAP-deleted, RAS-mutant metastatic pancreatic and lung cancer, alongside plans for a global Phase 3 trial.
The clinical update arrived during a sharp short-term pullback, with the 1-day share price return down 16.43% and the 30-day share price return down 6.34%. However, Tango Therapeutics still shows strong momentum, with a year-to-date share price return of 161.37% and a 1-year total shareholder return of 211.41%. This reflects how earlier trial readouts and expectations for future data have influenced both growth hopes and perceived risk.
Scan other high-risk, high-reward biotech ideas by comparing Tango Therapeutics with a hand-picked set of 21 high quality undiscovered gems in similar early-stage pipelines.
The swing in Tango Therapeutics now pits strong early trial signals against a cooler reaction in the share price. Is the latest move about changing fundamentals, or a reset in expectations on what is already priced in?
Most Popular Narrative: 50% Undervalued
Tango Therapeutics closed at $23.34, while the most followed narrative framework points to a fair value of $47.09. The gap in expectations is wide and rests heavily on how vopimetostat performs in late stage pancreatic cancer trials.
The main thing that has to go right is for vopimetostat based regimens, including RAS inhibitor combinations, to convert strong response and PFS data into successful late-stage trials in competitive indications like pancreatic cancer.
See why 1 investors see Tango Therapeutics as 50% undervalued.
Result: Fair Value of $47.09 (UNDERVALUED)
Still, the Tango Therapeutics story hinges on vopimetostat trial success and heavy reliance on a few lead assets, so any clinical setback could quickly unwind this undervaluation case.
Find out about the key risks to this Tango Therapeutics narrative.
Next Steps
Sentiment around Tango Therapeutics is split, so act while the data is fresh and weigh both sides of the debate by checking the 1 key reward and 3 important warning signs.
Looking for more Tango Therapeutics style ideas?
Do not stop with Tango Therapeutics alone. Broaden your watchlist now by lining up a few contrasting setups that can sharpen how you judge risk and potential reward.
- Target fresh opportunities with upside potential by scanning a focused 29 high quality undervalued stocks that filters for quality alongside pricing pressure that may have gone too far.
- Prioritize resilience and sleep-better-at-night holdings with a 30 resilient stocks with low risk scores that screens for stronger balance sheets and steadier business profiles.
- Hunt for future standouts early using a curated 7 elite penny stocks with strong financials that surfaces smaller, higher-risk candidates before they hit every headline.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com